Th17/Treg ratio in human graft-versus-host disease

Th17/Treg ratio in human graft-versus-host disease.

Th17 cells have never been explored in human graft-versus-host disease (GVHD). We studied the correlation between the presence of Th17 cells with histologic and clinical parameters. We first analyzed a cohort of 40 patients with GVHD of the gastrointestinal tract. Tumor necrosis factor (TNF), TNF receptors, and Fas expression, and apoptotic cells, CD4(+)IL-17(+) cells (Th17), and CD4(+)Foxp3(+)...

Graft Versus Host Disease

Commonly referred to as GVHD, graft-versus-host disease is a man-made condition that arises when patients are transplanted with donor tissue that is not identical to their own. Transplants from other individuals are called allogeneic (‘allo’ meaning ‘other’ and ‘geneic’ referring to ‘genes’). GVHD occurs after hematopoietic stem cell or bone marrow transplantation but is most commonly experienc...

Graft versus Host Disease

Definition Graft-versus-host disease (GVHD) is the most common complication of allogeneic hematopoietic stem cell transplantation (HSCT). In HSCT, the patient’s bone marrow is destroyed with chemotherapy and/or radiation and replaced by donor hematopoietic stem cells. In allogeneic HSCT the donor is usually a close family member or occasionally someone outside the family who has been found to b...

Graft-versus-host disease or graft-versus-host-like syndrome.

Acute graft versus host disease

Acute graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial cells after an inflammatory cascade that begins with the preparative regimen. About 35%-50% of hematopoietic stem cell transplant (HSCT) recipients will develop acute GVHD. The exact risk is...